Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$-0.42
EPS est.
$-0.74
EPS surprise
+43.47%
1-day move
+5.75%
Guardant Health's second-quarter results showed a significant earnings per share beat, which contributed to a positive stock reaction, rising 5.75%. However, the company did not report revenue figures, leaving investors without a complete picture of financial performance. The lack of guidance and management commentary adds uncertainty moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.42 | $-0.30 | +43.47% |
| Revenue | — | $339M | — |
No transcript is on record, and the analysis is based on numerical results only.
Guardant Health, Inc. is a healthcare company that focuses on non-invasive cancer detection and monitoring through its advanced genomic testing. With a market cap of $21 billion, it plays a significant role in the growing field of precision medicine, which aims to tailor treatments based on individual genetic profiles.
Last quarter
In Q1-2026, Guardant Health reported an EPS of $-0.45, which was better than the expected $-0.71, marking a significant positive surprise. However, revenue details were not disclosed, and the stock experienced a slight increase of 0.01% the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+38.61%
Avg 1-day reaction
+1.57%
Analysts are cautiously optimistic about Guardant Health's upcoming earnings, expecting a narrower loss compared to previous quarters. The consensus is that the company will continue to show improvements in its financial performance.
Bull case
If Guardant Health beats expectations, it could signal strong demand for its services and improved operational efficiencies, potentially driving the stock higher.
Bear case
On the other hand, if the company fails to meet expectations, it may raise concerns about its growth trajectory and market position, leading to a negative reaction from investors.
Key metrics to watch
EPS
$-0.30Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
$339MRevenue figures will provide insight into the company's growth and demand for its cancer detection services.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-0.30?
A beat on EPS would reinforce the positive momentum seen in the last few quarters and could lead to a strong market reaction.
Q2
What is the revenue figure compared to the consensus of $339M?
Revenue performance will be crucial in assessing the company's growth and market demand for its services.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±14.1%
Why consensus could be wrong
The Street may be underestimating the potential for Guardant Health to exceed revenue expectations due to increasing adoption of its testing services.
Supporting evidence
The company has consistently surprised on EPS, indicating better-than-expected cost management.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent trends in cancer detection indicate a growing market that Guardant Health is well-positioned to capitalize on.
Key risk
If revenue comes in above $345M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Guardant Health can sustain its recent positive earnings surprises and revenue growth.
Bull confirmed if
An EPS of $-0.26 or better, along with revenue exceeding $345M, would confirm the bull case.
Bear confirmed if
An EPS worse than $-0.36 and revenue below $332M would confirm the bear case.
What the market is pricing for the move.
Implied Move
±28.22%
Historical Avg
±3.8%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
61.6%
Smart-money positioning from the most recent 13F filings.
Institutional
100.95%
of float
Insider
3.98%
of float
Holders
801
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
7,622,935 sh · $1.3B
5.68%
-34.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Guardant Health beats expectations, history suggests the stock could rise by around 1.55% on the first day, confirming the positive trend.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
If the company misses expectations, the stock could drop significantly, as seen in past quarters where misses have led to declines.
The lines on the call that would change the story.
Price (T.Rowe) Associates Inc
6,514,952 sh · $1.1B
4.85%
-7.2%
Vanguard Capital Management LLC
5,755,857 sh · $968.9M
4.29%
2.3%
FMR, LLC
5,488,272 sh · $923.8M
4.09%
33.3%
Vanguard Portfolio Management LLC
5,445,785 sh · $916.7M
4.06%
-6.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.